Clinical Trials Logo

Non-melanomatous Skin Cancer clinical trials

View clinical trials related to Non-melanomatous Skin Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT00423397 Active, not recruiting - Clinical trials for Non-melanomatous Skin Cancer

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

Start date: September 2006
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PEG-interferon alfa-2a may interfere with the growth of tumor cells and slow the growth of skin cancer. Giving gefitinib together with PEG-interferon alfa-2a may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of PEG-interferon alfa-2a when given together with gefitinib and to see how well they work in treating patients with unresectable or metastatic skin cancer.

NCT ID: NCT00391300 Active, not recruiting - Melanoma (Skin) Clinical Trials

Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions

Start date: October 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: New diagnostic procedures, such as bioelectric field imaging, may help find and diagnose melanoma and other skin cancers. It may also be a less invasive way to check for skin cancer. PURPOSE: This phase I trial is studying bioelectric field imaging in diagnosing melanoma and other skin cancers in patients with skin lesions.

NCT ID: NCT00003097 Active, not recruiting - Clinical trials for Non-Melanomatous Skin Cancer

Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer

Start date: April 1989
Phase: Phase 2
Study type: Interventional

RATIONALE: A low-fat, balanced diet may prevent disease progression in patients with nonmelanomatous skin cancer. PURPOSE: Randomized phase II trial to study the effectiveness of a low-fat, balanced diet to prevent disease progression in patients with nonmelanomatous skin cancer.